00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
01:26 , Nov 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
19:13 , Aug 22, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Expression levels of a panel of inflammation-related mRNAs could help predict responses to PD-1 blockade in cancer. In tumor samples from 220 patients with nine different cancers, profiling of 680 genes for...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 5 (RANTES; CCL5); defensin α 1 (DEFA1; HNP-1)

Cardiovascular disease INDICATION: Inflammation; myocardial infarction (MI) Cell and mouse studies identified a peptide inhibitor of DEFA1- RANTES binding that could help treat MI and inflammation. In a proximity ligation assay in human endothelial cells,...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Oncolytic virus to enhance efficacy of chimeric antigen receptor (CAR)-specific T cells Mouse studies suggest oncolytic viruses could be used to enhance the anticancer efficacy...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Carolus, Alpha-1 Foundation deal

Carolus partnered with the not-for-profit's The Alpha-1 Project (TAP) Inc. subsidiary to characterize human biological samples for the presence of chemokine CC motif ligand 5 ( RANTES ; CCL5 )- platelet factor 4 ( PF4...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease Heparan sulfate glycosaminoglycan (HSGAG) In vitro studies identified heparan sulfate mimetics that could help treat inflammatory diseases. Sulfated HSGAGs...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Remune inactivated data

IMNR presented data on 11 HIV patients who had decreased levels of tumor necrosis factor after Remune therapy. As reported at the meeting of the Institute of Human Virology in Baltimore, levels of the RANTES...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer CC chemokine receptor 5 (CCR5; CD195) In vitro and mouse studies suggest CCR5 antagonists could help prevent breast cancer metastasis. In a genetic...